Finland · Delayed Price · Currency is EUR Aiforia Technologies Oyj Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 24% in 2025, with clinical sector up 68% year-over-year and accelerating in H2. Investments in technology and regulatory compliance drove portfolio expansion, while recurring revenue and major contracts in Europe and the U.S. support scale-up ambitions.
-
Order book grew 58% year-over-year, with clinical revenue up 60% and major European customer wins. Revenue was flat overall due to timing of deliveries, but strong pipeline and regulatory progress position the company for accelerated growth in H2 and beyond.
Fiscal Year 2024
-
Order book and revenue grew sharply, driven by clinical market expansion and major European contracts. EBITDA improved, cash reserves remain strong, and break-even is targeted by year-end 2024. Regulatory progress and new AI models support further growth.
-
Revenue grew 43% year-over-year, driven by major clinical wins in Europe and a growing order book. Profitability is targeted for 2027, with strong cash reserves and a focus on scaling delivery and expanding key accounts.